MariTide causes significant weight loss in trial participants

independent.co.uk

A new monthly weight loss drug, MariTide, has been found to help patients lose up to 20% of their body weight in a recent trial. The trial, published in The New England Journal of Medicine, involved nearly 600 participants and showed significant weight loss in those with obesity, and those with obesity and Type 2 diabetes. MariTide, developed by Amgen, also contains a monoclonal antibody. MariTide's monthly administration could offer a more convenient option compared to weekly injections of similar drugs like Ozempic, though gastrointestinal side effects were reported.


With a significance score of 5.6, this news ranks in the top 0.6% of today's 20677 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


MariTide causes significant weight loss in trial participants | News Minimalist